KR940011013A - Method for preparing sustained release somatropin formulation - Google Patents

Method for preparing sustained release somatropin formulation Download PDF

Info

Publication number
KR940011013A
KR940011013A KR1019920022551A KR920022551A KR940011013A KR 940011013 A KR940011013 A KR 940011013A KR 1019920022551 A KR1019920022551 A KR 1019920022551A KR 920022551 A KR920022551 A KR 920022551A KR 940011013 A KR940011013 A KR 940011013A
Authority
KR
South Korea
Prior art keywords
somatotropin
liposome
sustained release
formulation
lecithin
Prior art date
Application number
KR1019920022551A
Other languages
Korean (ko)
Inventor
김남중
조흥수
송맹석
이병건
Original Assignee
최근선
주식회사 럭 키
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 최근선, 주식회사 럭 키 filed Critical 최근선
Priority to KR1019920022551A priority Critical patent/KR940011013A/en
Priority to MYPI93000193A priority patent/MY134714A/en
Priority to CN93101680A priority patent/CN1103601C/en
Priority to SK1328-93A priority patent/SK279352B6/en
Priority to CZ932552A priority patent/CZ280429B6/en
Publication of KR940011013A publication Critical patent/KR940011013A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 레시틴 및 소마토트로괸의 수용액을 형성하여 리포좀 소마토트로핀을 제조하는 단계 사기 리포좀 소마토트로핀을 동결건조시키는 단계 및 상기 동결건조된 리포좀 소마토트로핀을 알파-토코페롤 아세테이트비히클에 현탁시키는 단계를 포함하는 약효의 지속기간이 길고 부작용이 없는 서방성 소마토트로핀 제제를 제조하는 방법에 관한 것이다.The present invention is to prepare a liposome somatotropin by forming an aqueous solution of lecithin and somatotropin lyophilizing liposome somatotropin and lyophilized liposome somatotropin alpha-tocopherol acetate vehicle The present invention relates to a method for preparing a sustained-release somatotropin preparation having a long duration and no side effects, including suspending the drug.

Description

서방성 소마트로핀 제제의 제조방법Method for preparing sustained release somatropin formulation

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도 및 제2도는 본 발명의 제제를 젖소에 투여하였을 때, 우유 생산의 효과를 도시하는 그래프,1 and 2 are graphs showing the effect of milk production when the formulation of the present invention is administered to cows,

제3도는 본 발명의 제제를 성장 돼지에 투여하였을 때, 혈청의 PST 농도의 변화를 도시하는 그래프,3 is a graph showing the change in serum PST concentration when the formulation of the present invention is administered to a growing pig,

제4도는 본 발명의 제제를 성장 돼지에 투여하였을 때, 혈청의 요소 질소 농도의 변화를 도시하는 그래프,4 is a graph showing the change in serum urea nitrogen concentration when the formulation of the present invention is administered to a growing pig,

제5도는 본 발명의 제제를 성장 돼지에 투여하였을 때, 혈청의 인슬린형 성장인자 I의 농도 변화를 도시하는 그래프.5 is a graph showing the change in the concentration of insulin growth factor I in serum when the formulation of the present invention is administered to a growing pig.

Claims (6)

레시틴 및 소마토트로핀의 수용액을 형성하여 리포좀 소마토트로핀을 제조하는 단계, 상기 리포좀 소마토트로핀을 동결건조시키는 단계, 및 상기 동결건조된 리포좀 소마토트로핀을 알파-토코페롤 아세테이트 비히클에 현탁시키는 단계를 포함하는 것을 특징으로 하는 서방성 소마토트로핀 제제의 제조방법.Forming an aqueous solution of lecithin and somatotropin to prepare liposome somatotropin, lyophilizing the liposome somatotropin, and lyophilized liposome somatotropin to the alpha-tocopherol acetate vehicle Sustained release somatotropin preparation comprising the step of suspending. 제1항에 있어서, 상기 소마토트로핀을 소 소마토트로핀, 돼지 소마토트로핀 및 양 소마토트로핀으로 구성된 군에서 선택하는 방법.The method of claim 1 wherein said somatotropin is selected from the group consisting of bovine somatotropin, porcine somatotropin and sheep somatotropin. 제1항 또는 제2항에 있어서, 상기 소마토트로핀을 재조합 DNA 기술로 제조하는 방법.The method of claim 1 or 2, wherein the somatotropin is prepared by recombinant DNA technology. 제1항에 있어서, 상기 레시틴은 대두 또는 계란 노른자에서 추출된 것임을 특징으로 하는 방법.The method of claim 1, wherein the lecithin is extracted from soy or egg yolk. 제1항에 있어서, 상기 동결건조된 리포좀 소마토트로핀이 10 내지 30 중량%이고, 알파-토코페롤 아세테이트가 70 내지 90 중량%인 방법.The method of claim 1, wherein the lyophilized liposome somatotropin is 10-30 wt% and the alpha-tocopherol acetate is 70-90 wt%. 제5항에 있어서, 상기 동결건조된 리포좀 소마토트로핀이 소마토트로핀 70 내지 80 중량 % 및 레시틴 20 내지 30 중량% 함량 범위에서 선택되는 방법.The method of claim 5, wherein the lyophilized liposome somatotropin is selected from the range of 70-80 wt% somatotropin and 20-30 wt% lecithin. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019920022551A 1992-11-27 1992-11-27 Method for preparing sustained release somatropin formulation KR940011013A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1019920022551A KR940011013A (en) 1992-11-27 1992-11-27 Method for preparing sustained release somatropin formulation
MYPI93000193A MY134714A (en) 1992-11-27 1993-02-06 Release-controlled somatotropin composition and method for the preparation thereof
CN93101680A CN1103601C (en) 1992-11-27 1993-02-24 Release-controlled somatotropin composition and method for prepartion thereof
SK1328-93A SK279352B6 (en) 1992-11-27 1993-11-26 Method of somatotropin agent preparation with controlled release
CZ932552A CZ280429B6 (en) 1992-11-27 1993-11-26 Somatotropic preparation with controlled release, and process for preparing thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920022551A KR940011013A (en) 1992-11-27 1992-11-27 Method for preparing sustained release somatropin formulation

Publications (1)

Publication Number Publication Date
KR940011013A true KR940011013A (en) 1994-06-20

Family

ID=19344061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920022551A KR940011013A (en) 1992-11-27 1992-11-27 Method for preparing sustained release somatropin formulation

Country Status (5)

Country Link
KR (1) KR940011013A (en)
CN (1) CN1103601C (en)
CZ (1) CZ280429B6 (en)
MY (1) MY134714A (en)
SK (1) SK279352B6 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365678B1 (en) * 2000-03-24 2002-12-26 주식회사 엘지생명과학 The somatotropin formulation of improved syringeability
KR100423895B1 (en) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 Compositions of suspensions of ceftiofur hydrochloride

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751769B (en) * 2013-12-25 2015-08-19 楼秀余 A kind of lyophilizing recombinant human somatropin capsule and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
JPS63502117A (en) * 1986-02-10 1988-08-18 リポソ−ム　テクノロジ−，インコ−ポレイテッド Controlled release liposome delivery system
DE3853079T3 (en) * 1987-12-04 2000-11-09 The Liposome Co.,Inc. HIGH STABILITY LIPOSOME AND METHOD FOR THE PRODUCTION AND USE.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365678B1 (en) * 2000-03-24 2002-12-26 주식회사 엘지생명과학 The somatotropin formulation of improved syringeability
KR100423895B1 (en) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 Compositions of suspensions of ceftiofur hydrochloride

Also Published As

Publication number Publication date
SK132893A3 (en) 1994-07-06
SK279352B6 (en) 1998-10-07
CN1087277A (en) 1994-06-01
CZ255293A3 (en) 1994-06-15
MY134714A (en) 2007-12-31
CZ280429B6 (en) 1996-01-17
CN1103601C (en) 2003-03-26

Similar Documents

Publication Publication Date Title
ATE184480T1 (en) METHOD FOR PRODUCING MEDICINAL PREPARATIONS WITH DELAYED RELEASE OF ACTIVE INGREDIENTS
US4447355A (en) Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
JPS57140724A (en) Heat-treatment of aqueous solution containing cold insoluble globulin
KR960700690A (en) Process for producing liposome composition
DE69519670D1 (en) MICROPARTICLE WITH DELIVERY SYSTEM
KR910016322A (en) Compositions stable for parenteral administration and methods for preparing the same
DE69623003D1 (en) Stable protein phospholipid compositions and method of manufacture
KR850007378A (en) Process for preparing stabilizing composition of interleukin-2
RU93034781A (en) MICROCapsule FOR LONG-TERM RELEASE OF PHYSIOLOGICALLY ACTIVE PEPTIDE
PT94842A (en) METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROPARTICULES OF A LACTIC AND GLYCOLIC ACID COPOLYMER AND INCORPORATING AS AN ACTIVE SUBSTANCE A PAMOATE, TANATE, ESTEARATE OR PALMITATE OF A NATURAL OR SYNTHETIC PEPTIDE
DK0454898T3 (en) Glycosaminoglycan modified protein, method of producing the protein, pharmaceutical preparations containing the protein and use of the protein
DE3852116D1 (en) Production of proteins in active form.
ATE89740T1 (en) METHODS OF PREPARATION AND COMPOSITIONS OF COLLAGEN DERIVATIVES.
ATE114319T1 (en) PRODUCTION OF PROTEINS IN ACTIVE FORMS.
EA199900751A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LYOPHILIZED LIPOSOMES, INCLUDING INCAPSULATED ACTIVE INGREDIENT, PRACTICALLY INSOLUBLE IN WATER, AND METHOD FOR PREPARING THE COMPOSITION
Garbi et al. Embedding in a collagen gel stabilizes the polarity of epithelial cells in thyroid follicles in suspension culture
KR880013572A (en) Mixed crystals of insulin and insulin derivatives, preparation methods thereof, medicaments containing the same and uses thereof
KR890001475A (en) Dough inhibitor
KR940011013A (en) Method for preparing sustained release somatropin formulation
DE69023648D1 (en) PRODUCTION OF A VIRUS AND CLEANING OF VIRUS COATING PROTEINS FOR VACCINE USE.
EP0382779A4 (en) Tocopherol-based pharmaceutical systems
ATE160588T1 (en) EXTRACT CONSISTING OF BACTERIAL PROTEINS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THIS EXTRACT
KR970706832A (en) LIPID METABOLISM AMELIORANT
ATE168115T1 (en) DISSOLVING PROTEINS IN ACTIVE FORM
Cherel et al. Changes in body mass and plasma metabolites during short-term fasting in the king penguin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application